JACK-MA/ALIBABA
29.3.2020 07:00:09 CEST | Business Wire | Press release
The Jack Ma Foundation and the Alibaba Foundation today announced donations of essential medical supplies to seven more countries, namely Azerbaijan, Bhutan, India, Kazakhstan, Kyrgyzstan, Uzbekistan and Vietnam.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200328005024/en/
Collectively, these seven countries will receive a total of 1.7 million face masks, 165,000 test kits as well as protective clothing and medical equipment such as ventilators and forehead thermometers. With this announcement, the two Foundations have now donated essential medical supplies to 23 Asian countries totalling 7.4 million masks; 485,000 test kits; 100,000 sets of protective clothing along with other medical equipment.
The first batch of medical supplies for India arrived in Delhi last night and were received by the Indian Red Cross Society. Similar to the arrangement with the Italian Red Cross Society, the Indian charity will facilitate the distribution of these supplies in the country. The donations are expected to reach other countries in the coming days.
Mr. Neel Kamal Singh, Deputy Secretary, Indian Red Cross Society took receipt of the donations from Mr. Vivek Sehgal, Manager, Alibaba Cloud India, acting on behalf of the Jack Ma Foundation and the Alibaba Foundation. Ms. Ma Jia, Deputy Chief of Mission of the Embassy of China in India, was also present to show the embassy’s support towards this humanitarian initiative.
“Government of India has taken extensive steps to manage the COVID-19 situation. To supplement the efforts of government, Indian Red Cross has mobilised first tranche of supplies consisting of facemasks, protective body suits and essential medical equipment. This consignment, which was received yesterday, has been donated by Jack Ma Foundation and Alibaba Foundation. Indian Red Cross appreciates their magnanimity at this difficult juncture,” said Mr. R.K Jain, IAS (Rtd), Secretary General, Indian Red Cross .
“We are one with the global community in the intense battle to protect all families against Covid-19. We are committed to doing everything we can to make a difference, most importantly by sourcing these supplies and overcoming logistical challenges to get the medical supplies to where they are needed as fast as we can,” said the Jack Ma Foundation .
These donations are among a number of aid initiatives from the Alibaba Foundation and Jack Ma Foundation to support the areas of the world affected by the Covid-19 crisis, sourcing and delivering various types of medical supplies to countries across Asia, North America, Latin America, Europe and Africa. The donation by the two foundations to Vietnam is in addition to the recent donation by Lazada Group, Alibaba Group’s local e-commerce business unit in Southeast Asia.
More initiatives and donations may be announced in the coming days and weeks.
The Jack Ma Foundation and the Alibaba Foundation also supported the publication of a handbook with key lessons and experience from doctors, healthcare workers, and hospital administrators at the First Affiliated Hospital, Zhejiang University School of Medicine (FAHZU), who were on the frontline of COVID-19 treatment in China and crucial to slowing its spread. The handbook is available for global medical health professionals at https://covid-19.alibabacloud.com/ .
Follow @JackMa and @foundation_ma on Twitter for the latest efforts of Jack Ma Foundation and Alibaba Foundation to support the global fight against COVID-19.
About Jack Ma Foundation
Established by Jack Ma, the founder of Alibaba Group, the Jack Ma Foundation was founded on 15 December 2014 and has been focusing on education, entrepreneurship, women’s leadership, and the environment. The Foundation aspires to be a reliable, participative, and sustainable philanthropic organization. The Jack Ma Foundation has so far supported projects worldwide including the Jack Ma Rural Education Program, the Africa Netpreneur Prize Initiative, the Ma & Morley Scholarship Program, and Jordan's Queen Rania Foundation. Additionally, the Foundation has also funded a number of projects in its priority areas. The Jack Ma Foundation is committed to empowering rural educators, entrepreneurs, rural children, young start-ups, and women to equip them for the future and to help build a happier, healthier, more sustainable and more inclusive society.
About Alibaba Foundation
The Alibaba Foundation, established in December 2011, aims to create a culture that encourages people to get involved in philanthropy, make it sustainable and genuinely contribute to civil society and nature. Its key funding aspects include water protection, environmental awareness promotion and development of green organizations. Alibaba Group is committed to devoting a percentage of its annual income to the Alibaba Foundation to ensure stable long-term funding that will allow for timely response in the event of natural disasters or expansion of philanthropic projects.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200328005024/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Yubico Appoints Poupak Modirassari Enbom as Chief Marketing Officer to Accelerate Global Momentum and Drive Market Leadership30.3.2026 15:00:00 CEST | Press release
Yubico (NASDAQ STOCKHOLM: YUBICO), the creator of the most secure passkeys and a leading provider of hardware authentication security keys, today announced the appointment of Poupak Enbom as Chief Marketing Officer (CMO). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330278027/en/ Enbom joins Yubico at a pivotal moment as organizations worldwide accelerate the shift to phishing-resistant authentication and modern identity security in the age of AI. “We’re excited to welcome Poupak to Yubico,” said Jerrod Chong, acting chief executive officer, Yubico. “As the threat landscape evolves with AI-driven attacks and increasing automation, organizations are rethinking how they secure digital identities of both humans and AI agents at scale. She brings a unique combination of technical depth, global leadership, and customer-first mindset that will help us continue to expand our impact and support our customers and partners around
Westinghouse Celebrates Record-breaking 80 Years of Nuclear Fuel Manufacture at Springfields30.3.2026 14:00:00 CEST | Press release
Fuel manufactured at Springfields has generated enough energy to supply the UK’s electricity demand for 26 years, avoiding the emission of nearly 3 billion tonnes of CO2 The Westinghouse Springfields facility in Lancashire, UK, has marked a significant milestone as the oldest continuous nuclear fuel manufacturing site in the world, starting from its original license on the 28th, March 1946. The site was chosen by the UK Government to develop nuclear fuel for the world’s earliest civil nuclear power stations, as well as subsequent Magnox and Advanced Gas Reactors (AGR) reactors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330135973/en/ From left to right: Sophie Lemaire; Marc Chevrel; Rory O'Neill; Craig Boothby; and Robert Gofton, CEO at Nuclear Institute Across the last eight decades, the Springfields site has supported the UK nuclear fleet, manufacturing more than eight million AGR pins, sintering and pressing over 5
HistoSonics Treats First Patients Evaluating the Edison® Histotripsy System for the Treatment of Benign Prostatic Hyperplasia (BPH)30.3.2026 14:00:00 CEST | Press release
HistoSonics, the developer of the Edison® Histotripsy System and novel histotripsy therapy platform, today announced the successful treatments of the first patients in WOLVERINE, a prospective feasibility trial evaluating the Edison® Histotripsy System for the treatment of benign prostatic hyperplasia (BPH) at Prince of Wales Hospital in Hong Kong, a teaching hospital for The Chinese University of Hong Kong. The Edison System is a novel, non-invasive, image guided platform that uses the mechanical properties of focused ultrasound, called histotripsy, to destroy unwanted tissue without the need for invasive procedures, and with potentially fewer side effects than traditional, invasive therapies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330349844/en/ HistoSonics Non-Invasive Edison Histotripsy System. Image credit: HistoSonics WOLVERINE is a prospective, multi-center, single-arm feasibility trial designed to evaluate
Biocytogen Grants Taisho Pharmaceutical a License to its RenNano® Fully Human Heavy Chain-Only Antibody Discovery Platform30.3.2026 13:00:00 CEST | Press release
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced that it has entered into a platform license agreement with Taisho Pharmaceutical Co., Ltd. (“Taisho”), granting Taisho the right to access and use Biocytogen’s proprietary RenNano® fully human heavy chain-only antibody (HCAbs) discovery platform for its internal research and development programs. Under the terms of the agreement, Taisho will leverage RenNano® mice to enable the generation and screening of fully human HCAbs in vivo and to support downstream research associated with antibody discovery. Financial terms of the agreement have not been disclosed. “We are very pleased to enter into this collaboration with Taisho,” said Dr. Yuelei Shen, President and CEO of Biocytogen. “RenNano® is a robust and powerful fully human VHH discovery platform that pro
Meiji Seika Pharma Invests in Centivax to Develop Next Generation Universal Vaccine Platform30.3.2026 13:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Head Office: Chuo-ku, Tokyo, President and Representative Director: Toshiaki Nagasato) today announced a strategic investment in Centivax, Inc. (Head Office: South San Francisco, CA, USA), a biotechnology company developing next-generation vaccines and therapies for universal protection against highly diverse targets. Centivax’s lead program includes a universal seasonal influenza vaccine (Centi-Flu 01) currently in a Phase 1 clinical study. Unlike conventional seasonal flu vaccines, which must be manufactured annually based on recommended candidate vaccine viruses, Centivax’s platform focuses both antibody and cellular immune responses on conserved regions of the influenza virus that cannot mutate and are shared across strains and distant subtypes. This approach aims to generate broad, consistent, and durable immunity against both seasonal and pandemic influenza. Meiji’s strategic investment aims to accelerate the advancement of Centi-Flu 01 and further a
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom